SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern
Open accessThe DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
Abstract
SARS-CoV-2 from alpha to epsilon: As battles to contain the COVID-19 pandemic continue, attention is focused on emerging variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus that have been deemed variants of concern because they are resistant to antibodies elicited by infection or vaccination or they increase transmissibility or disease severity. Three papers used functional and structural studies to explore how mutations in the viral spike protein affect its ability to infect host cells and to evade host immunity. Gobeil et al . looked at a variant spike protein involved in transmission between minks and humans, as well as the B1.1.7 (alpha), B.1.351 (beta), and P1 (gamma) spike variants; Cai et al . focused on the alpha and beta variants; and McCallum et al . discuss the properties of the spike protein from the B1.1.427/B.1.429 (epsilon) variant. Together, these papers show a balance among mutations that enhance stability, those that increase binding to the human receptor ACE2, and those that confer resistance to neutralizing antibodies. —VV
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2. B.1.427/B.1.429 S pseudotyped virus neutralization by vaccine-elicited and COVID-19 convalescent plasma. (A, B, E, and F) Neutralizing Ab titers [mean inhibition dilution (ID50)] shown as pairwise connected [(A) and (E)] or GMT [(B) and (F)] against MLV [(A) and (B)] or VSV [(E) and (F)] pseudotyped viruses harboring G614 SARS-CoV-2 S or B.1.427/B.1.429 (B.1.429) S determined using plasma from individuals who received two doses of the Moderna mRNA-1273 vaccine (blue). (C, D, G, and H) Neutralizing Ab titers (ID50) shown as pairwise connected [(C) and (G)] or GMT [(D) and (H)] against MLV [(C) and (D)] or VSV [(G) and (H)] pseudotyped viruses harboring G614 SARS-CoV-2 S or B.1.427/B.1.429 (B.1.429) S determined using plasma from individuals who received two doses of the Pfizer/BioNtech BNT162b2 mRNA vaccine (red). (I and J) Neutralizing Ab ID50 (I) and GMT (J) titers against VSV pseudotyped viruses harboring D614 SARS-CoV-2 S, B.1.427/B.1.429 S, B.1.1.7 S, B.1.351 S, or P.1 S determined using plasma from naïve (blue) and previously infected (red) individuals who received two doses of the Pfizer/BioNtech BNT162b2 mRNA vaccine. “Naïve” indicates vaccinated individuals who had not been previously infected with SARS-CoV-2; “immune” refers to vaccinated individuals who had been previously infected with SARS-CoV-2. (K and L) Neutralizing Ab ID50 (K) and GMT (L) titers against VSV pseudotyped viruses harboring D614 SARS-CoV-2 S, B.1.427/B.1.429 S, B.1.1.7 S, B.1.351 S, or P.1 S determined using plasma from convalescent individuals who were infected with WT SARS-CoV-2. Neutralization data shown in (A) to (H) and (I) to (L) were performed using 293T-ACE2 and VeroE6-TMPRSS2, respectively. Data are average of n = 2 replicates.](https://figures.cochat.ai/paper-figures/e2b6f8f874fc4753bb3a1e70b39ac8ee/sars-cov-2-immune-evasion-by-the-b-1-427-b-1-429-variant-of-concern-figure-2.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This signal peptide modification resulted in a total loss of neutralization by ten NTD-specific antibodies [40].”
From Waves and variants of SARS-CoV-2: understanding the causes and effect of the COVID-19 catastrophe (2022) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of 34 convalescent plasma samples from persons infected with the Alpha variant, 59% had 3-fold to 10-fold reduced neutralizing activity and 18% had >10-fold reduced neutralizing activity to the Beta variant 99,104,221 .”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [221]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A novel mechanism of immune evasion was studied in the Epsilon variant, where the other two mutations remodeled NTD by shifting the signal peptide cleavage site in the NTD antigenic supersite and forming a new disulfide bond.”
From Waves and variants of SARS-CoV-2: understanding the causes and effect of the COVID-19 catastrophe (2022) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability
Katoh, K., & Standley, D. M. (2013) · Molecular Biology and Evolution · doi:10.1093/molbev/mst010 · Cited by 46,209
UCSF Chimera—A visualization system for exploratory research and analysis
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 45,828
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Self-citationLiebschner, D., Afonine, P. V., Baker, M. L., Bunkóczi, G., Chen, V. B., Croll, T. I., Hintze, B., Hung, L.-W., Jain, S., McCoy, A. J., et al. (2019) · Acta Crystallographica Section D Structural Biology · doi:10.1107/s2059798319011471 · Cited by 7,953
UCSF ChimeraX: Meeting modern challenges in visualization and analysis
Goddard, T. D., Huang, C. C., Meng, E. C., Pettersen, E. F., Couch, G. S., Morris, J. H., & Ferrin, T. E. (2018) · Protein Science · doi:10.1002/pro.3235 · Cited by 5,267
New tools for automated high-resolution cryo-EM structure determination in RELION-3
Zivanov, J., Nakane, T., Forsberg, B. O., Kimanius, D., Hagen, W. J., Lindahl, E., & Scheres, S. H. (2018) · eLife · doi:10.7554/elife.42166 · Cited by 4,621
Cited by
Items 101–200 of 426
Cao, L., Lou, J., Chan, S. Y., Zheng, H., Liu, C., Zhao, S., Li, Q., Mok, C. K. P., Chan, R. W. Y., Chong, M. K. C., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01877-1 · Cited by 49
Ahmad, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.742167 · Cited by 48
Horiuchi, S., Oishi, K., Carrau, L., Frere, J. J., Møller, R., Panis, M., & tenOever, B. R. (2021) · Science Immunology · doi:10.1126/sciimmunol.abm3131 · Cited by 48
Tragni, V., Preziusi, F., Laera, L., Onofrio, A., Mercurio, I., Todisco, S., Volpicella, M., Grassi, A., & Pierri, C. L. (2022) · The EPMA Journal · doi:10.1007/s13167-021-00267-w · Cited by 52
Bhattacharya, M., Chatterjee, S., Sharma, A. R., Lee, S., & Chakraborty, C. (2022) · Folia Microbiologica · doi:10.1007/s12223-022-01001-3 · Cited by 55
Cheng, M. H., Krieger, J. M., Banerjee, A., Xiang, Y., Kaynak, B., Shi, Y., Arditi, M., & Bahar, I. (2022) · iScience · doi:10.1016/j.isci.2022.103939 · Cited by 47
“…et al., 2021), cryo-EM (Cai et al., 2021; Dejnirattisai et al., 2021b; Du et al., 2021; Gobeil et al., 2021; Han et al., 2021; Liu et al., 2021a; McCallum et al., 2021a, 2021b; Pymm et al., 2021; Supasa et al., 2021; Wang et al., 2021a; Zhang et al., 2021a; Zhu et al., 2021), computational…”
InfluentialChen, Y., Sun, L., Ullah, I., Beaudoin-Bussières, G., Anand, S. P., Hederman, A. P., Tolbert, W. D., Sherburn, R. T., Nguyen, D. N. P., Marchitto, L., et al. (2022) · Science Advances · doi:10.1126/sciadv.abn4188 · Cited by 51
Stadler, E., Chai, K. L., Schlub, T. E., Cromer, D., Khan, S. R., Polizzotto, M. N., Kent, S. J., Beecher, C., White, H., Turner, T., et al. (2023) · The Lancet Microbe · doi:10.1016/s2666-5247(23)00194-5 · Cited by 48
Ni, D., Turelli, P., Beckert, B., Nazarov, S., Uchikawa, E., Myasnikov, A. G., Pojer, F., Trono, D., Stahlberg, H., & Lau, K. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011206 · Cited by 50
Molecular insights into the adaptive evolution of SARS-CoV-2 spike protein
Yao, Z., Zhang, L., Duan, Y., Tang, X., & Lü, J. (2024) · Journal of Infection · doi:10.1016/j.jinf.2024.106121 · Cited by 52
SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs
Iketani, S., & Ho, D. D. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.03.008 · Cited by 51
Structure and Mutations of SARS-CoV-2 Spike Protein: A Focused Overview
Mehra, R., & Kepp, K. P. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00433 · Cited by 45
The Development of SARS-CoV-2 Variants: The Gene Makes the Disease
Pérez-Gómez, R. (2021) · Journal of Developmental Biology · doi:10.3390/jdb9040058 · Cited by 48
Cao, L., Li, Y., Yang, S., Li, G., Zhou, Q., Sun, J., Xu, T., Yang, Y., Liao, R., Shi, Y., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abm7621 · Cited by 48
“Vaccine-induced or naturally-acquired protective immunity necessary to disrupt transmission chains had been hampered by the rapid evolution and emergence of VOCs ( 8 – 13 , 54 ).”
Al-Karmalawy, A. A., Soltane, R., Elmaaty, A. A., Tantawy, M. A., Antar, S. A., Yahya, G., Chrouda, A., Pashameah, R. A., Mustafa, M., Mraheil, M. A., et al. (2021) · Vaccines · doi:10.3390/vaccines9111317 · Cited by 44
Neutrophils and lymphopenia, an unknown axis in severe COVID-19 disease
Peñaloza, H. F., Lee, J. S., & Ray, P. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009850 · Cited by 47
“developing countries and the emergence of variants of concern [11,12] raise the importance of understanding the mechanisms behind the dysregulated immune response that leads to severe COVID-19 in some individuals.”
BackgroundPseudoscience and fraudulent products for COVID-19 management
Chavda, V. P., Sonak, S. S., Munshi, N. K., & Dhamade, P. N. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-022-21967-4 · Cited by 50
“For people without scientific knowledge, understanding and interpreting the graphs of data of COVID infections is difficult (Miller 2020).”
BackgroundInhalation of ACE2-expressing lung exosomes provides prophylactic protection against SARS-CoV-2
Wang, Z., Hu, S., Popowski, K. D., Liu, S., Zhu, D., Mei, X., Li, J., Hu, Y., Dinh, P., Wang, X., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45628-x · Cited by 49
“Editorial Note: Figure on page 11 in this Peer Review File has been amended to remove third-party material where no permission to publish could be obtained.”
Ridgway, H. F., Moore, G. J., Mavromoustakos, T., Tsiodras, S., Ligielli, I., Kelaidonis, K., Chasapis, C. T., Gadanec, L. K., Zulli, A., Apostolopoulos, V., et al. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.04.010 · Cited by 45
Schrörs, B., Riesgo-Ferreiro, P., Sorn, P., Gudimella, R., Bukur, T., Rösler, T., Löwer, M., & Şahin, U. (2021) · PLoS ONE · doi:10.1371/journal.pone.0249254 · Cited by 42
Carroll, T. D., Fox, D., van Doremalen, N., Ball, E. E., Morris, M. K., Sotomayor-González, A., Servellita, V., Rustagi, A., Yinda, C. K., Fritts, L., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1009914 · Cited by 40
“Further, the L452R mutation reduced neutralizing activity in a subset of receptor binding domain-specific monoclonal (m) Abs tested, and the S13I and W152C mutations abrogated neutralization by all N-terminal domain-specific mAbs tested [8].”
BackgroundCuadros, D., Moreno, C., Musuka, G., Miller, F., Coule, P., & Mackinnon, N. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.898101 · Cited by 43
Gardner, B. J., & Kilpatrick, A. M. (2024) · Viruses · doi:10.3390/v16030479 · Cited by 49
Triveri, A., Serapian, S. A., Marchetti, F., Doria, F., Pavoni, S., Cinquini, F., Moroni, E., Rasola, A., Frigerio, F., & Colombo, G. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00857 · Cited by 41
SARS-CoV-2 intra-host evolution during prolonged infection in an immunocompromised patient
Quaranta, E. G., Fusaro, A., Giussani, E., D’Amico, V., Varotto, M., Pagliari, M., Giordani, M. T., Zoppelletto, M., Merola, F., Antico, A., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.06.023 · Cited by 43
Omicron BA.1 and BA.2 neutralizing activity elicited by a comprehensive panel of human vaccinesPreprint
Bowen, J. E., Sprouse, K. R., Walls, A. C., Mazzitelli, I. G., Logue, J. K., Franko, N., Ahmed, K., Ansari, A. S., Cameroni, E., Gori, A., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.15.484542 · Cited by 42
“The ongoing COVID-19 pandemic has led to the emergence of SARS-CoV-2 variants with increased transmissibility, viral fitness and immune evasion ( 1 – 10 ).”
BackgroundSelf-citationRyu, D.-K., Kang, B., Noh, H., Woo, S., Lee, M., Nuijten, P. M., Kim, J., Seo, J.-M., Kim, C.-M., Kim, M., et al. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.09.023 · Cited by 44
Romagnoli, A., D’Agostino, M., Pavoni, E., Ardiccioni, C., Motta, S., Crippa, P., Biagetti, G., Notarstefano, V., Rexha, J., Perta, N., et al. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101729 · Cited by 43
The rapid adaptation of SARS-CoV-2–rise of the variants: transmission and resistance
Soh, S. M., Kim, Y., Kim, C., Jang, U. S., & Lee, H.-R. (2021) · The Journal of Microbiology · doi:10.1007/s12275-021-1348-5 · Cited by 52
Queirós-Reis, L., da Silva, P. G., Gonçalves, J., Brancale, A., Bassetto, M., & Mesquita, J. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910836 · Cited by 43
“In the Delta variant, mutations T19R, E156-, F157-and R158G severely affect NTD directed Abs, due to the adoption of an alpha-helical conformation, instead of the original β - strand [64,68].”
SARS-CoV-2 spike E156G/Δ157-158 mutations contribute to increased infectivity and immune escape
Mishra, T. K., Joshi, G., Kumar, A., Dalavi, R., Pandey, P., Shukla, S., Mishra, R. K., & Chande, A. G. (2022) · Life Science Alliance · doi:10.26508/lsa.202201415 · Cited by 45
“…with the neutralizing antibodies, we mapped the interaction interface from the 17 antibodies reported earlier (Chi et al, 2020; Wang et al, 2020; McCallum et al, 2021a, 2021b; Cao et al, 2021b; Liu et al, 2021b), recognizing the spike NTD that showed enrichment of 37 residues: Q14, C15, V16,…”
MethodAntibody escape and cryptic cross-domain stabilization in the SARS-CoV-2 Omicron spike protein
Javanmardi, K., Segall-Shapiro, T. H., Chou, C., Boutz, D. R., Olsen, R. J., Xie, X., Xia, H., Shi, P., Johnson, C. D., Annapareddy, A., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.07.016 · Cited by 42
Focosi, D., Tuccori, M., Baj, A., & Maggi, F. (2021) · Viruses · doi:10.3390/v13071211 · Cited by 40
Samsudin, F., Raghuvamsi, P. V., Petruk, G., Puthia, M., Petrlová, J., MacAry, P. A., Anand, G. S., Bond, P. J., & Schmidtchen, A. (2022) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjac058 · Cited by 39
Aiello, A., Fard, S. N., & Goletti, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1244556 · Cited by 41
Chen, R. E., Gorman, M. J., Zhu, D. Y., Carreño, J. M., Yuan, D., VanBlargan, L. A., Burdess, S., Lauffenburger, D. A., Kim, W., Turner, J. S., et al. (2021) · Med · doi:10.1016/j.medj.2021.11.004 · Cited by 38
da Silva, S. J. R., de Lima, S. C., da Silva, R. C., Kohl, A., & Pena, L. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.836826 · Cited by 38
Wang, M., Zhang, L., Li, Q., Wang, B., Liang, Z., Sun, Y., Nie, J., Wu, J., Su, X., Qu, X., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.2008775 · Cited by 35
“Simultaneously, L452R can escape cellular immunity [27], while neutralizing protection against L452R by mAbs, convalescent sera, and vaccineinduced immune sera is significantly reduced [48,49].”
BackgroundNeerukonda, S. N., Vassell, R. A., Lusvarghi, S., Wang, R., Echegaray, F., Bentley, L., Eakin, A. E., Erlandson, K. J., Katzelnick, L. C., Weiss, C. D., et al. (2021) · Viruses · doi:10.3390/v13122485 · Cited by 31
“The L452R is centrally located in the receptor-binding site and is a known resistance substitution for several mAbs [23,26].”
BackgroundInfluentialBroad receptor tropism and immunogenicity of a clade 3 sarbecovirus
Lee, J., Zepeda, S. K., Park, Y., Taylor, A. L., Quispe, J. D., Stewart, C., Leaf, E. M., Treichel, C., Corti, D., King, N. P., et al. (2023) · Cell Host & Microbe · doi:10.1016/j.chom.2023.10.018 · Cited by 36
Self-citationRen, W., Ju, X., Gong, M., Lan, J., Yu, Y., Long, Q., Kenney, D., O’Connell, A. K., Zhang, Y. L., Zhong, J., et al. (2022) · mBio · doi:10.1128/mbio.00099-22 · Cited by 41
The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines
Jiang, Y., Wu, Q. Y., Song, P., & You, C. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.806641 · Cited by 36
Bassi, J., Giannini, O., Silacci-Fregni, C., Pertusini, L., Hitz, P., Terrot, T., Franzosi, Y., Muoio, F., Saliba, C., Meury, M., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263328 · Cited by 34
“Indeed, naïve individuals were shown to develop lower titers of neutralizing antibodies to SARS-CoV-2 variants compared to previously infected individuals after two mRNA vaccine doses [35], indicating that vaccination may boost the neutralizing antibody response in dialysis patients after infection [53].”
BackgroundMethodResultSelf-citationThe SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccinesPreprint
Liu, Y., Arase, N., Kishikawa, J.-I., Hirose, M., Li, S., Tada, A., Matsuoka, S., Arakawa, A., Akamatsu, K., Ono, C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.22.457114 · Cited by 33
“L452 has been reported to be an epitope for some, but not most, neutralizing antibodies (McCallum et al., 2021; Wang et al., 2021b).”
BackgroundInfluentialMutational dynamics of SARS-CoV-2: Impact on future COVID-19 vaccine strategies
Faraji, N., Zeinali, T., Joukar, F., Aleali, M. S., Eslami, N., Shenagari, M., & Mansour‐Ghanaei, F. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30208 · Cited by 36
“Of particular interest is the B.1.617.1 lineage, characterized by the “ double mutant ” E484Q and L452R mutations, conferring immune evasion capabilities [104 – 106].”
BackgroundInfluentialChadha, J., Khullar, L., & Mittal, N. (2021) · Environmental Microbiology · doi:10.1111/1462-2920.15687 · Cited by 38
“Similar investigations have also disclosed the ability of the B.1.429 variant to overcome antibody-mediated neutralization, eliciting immune escape (McCallum et al., 2021).”
ResultInfluentialAdvances in mRNA and other vaccines against MERS-CoV
Tai, W., Zhang, X., Yang, Y., Zhu, J., & Du, L. (2021) · Translational research · doi:10.1016/j.trsl.2021.11.007 · Cited by 41
“It has been shown that both vector and mRNA-based SARS-CoV2 vaccines derived from the S protein of the original strain (Wuhan-Hu-1), including the full-length S protein, S1 subunit, and RBD fragment, were found less effective in neutralizing variants with S mutations (eg, in the RBD and NTD of the S1 subunit).(90,121-…”
BackgroundXu, K., Fan, C., Han, Y., Dai, L., & Gao, G. F. (2022) · International Immunology · doi:10.1093/intimm/dxac031 · Cited by 32
Cocherie, T., Zafilaza, K., Leducq, V., Marot, S., Cálvez, V., Marcelin, A., & Todesco, È. (2022) · Microorganisms · doi:10.3390/microorganisms11010030 · Cited by 35
“altering the 448–456 region of the S protein [61,62].”
BackgroundYan, Q., Hou, R., Huang, X., Zhang, Y., He, P., Zhang, Y., Liu, B., Wang, Q., Rao, H., Chen, X., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2140611 · Cited by 31
“It has milder effect in reducing neutralizing activity of convalescent sera [2,5,6].”
BackgroundJensen, J. L., Sankhala, R. S., Dussupt, V., Bai, H., Hajduczki, A., Lal, K. G., Chang, W. C., Martinez, E. J., Peterson, C. E., Golub, E. S., et al. (2023) · Journal of Virology · doi:10.1128/jvi.01596-22 · Cited by 32
Salazar–García, M., Acosta-Contreras, S., Martinez, G. R., Cruz‐Rangel, A., Flores-Alanis, A., Patiño‐López, G., & Luna-Pineda, V. M. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.817200 · Cited by 33
Structural Immunology of SARS ‐ CoV ‐2
Yuan, M., & Wilson, I. A. (2024) · Immunological Reviews · doi:10.1111/imr.13431 · Cited by 29
Casasnovas, J. M., Margolles, Y., Noriega, M. A., Guzmán, M. Á., Arranz, R., Melero, R., Casanova, M., Sánchez, J. A. C., de Oya, N. J., Gastaminza, P., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.863831 · Cited by 33
Mertens, J. C., Coppens, J., Loens, K., Mercier, M. L., Xavier, B. B., Lammens, C., Vandamme, S., Jansens, H., Goossens, H., & Matheeussen, V. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.09.007 · Cited by 28
VarEPS: an evaluation and prewarning system of known and virtual variations of SARS-CoV-2 genomes
Sun, Q., Shu, C., Shi, W., Luo, Y., Fan, G., Nie, J., Bi, Y., Wang, Q., Qi, J., Lü, J., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab921 · Cited by 30
“L452R is an important mutation that has commonly appeared in the recently prevalent Alpha, Delta, Epsilon, Iota and Kappa strains, and it is reported that the variants can reduce sensitivity to neutralizing antibodies (8).”
BackgroundTherapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?
Zhang, J., Zhang, H., & Sun, L. (2022) · mAbs · doi:10.1080/19420862.2022.2031483 · Cited by 29
Free energy perturbation calculations of mutation effects on SARS-CoV-2 RBD::ACE2 binding affinity
Sergeeva, A. P., Katsamba, P. S., Liao, J., Sampson, J. M., Bahna, F., Mannepalli, S., Morano, N. C., Shapiro, L., Friesner, R. A., & Honig, B. (2023) · Journal of Molecular Biology · doi:10.1016/j.jmb.2023.168187 · Cited by 27
“Some studies relied on monomeric ACE2 and RBD [21, 22, 24, 25, 27-30], whereas others used at least one of the molecule in a multimeric form (trimeric spike, dimeric ACE2 or monomeric ACE2 fused to a dimeric Fc tag) [20, 25, 26, 31, 32, 64].”
InfluentialShooting at a Moving Target—Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development
Günl, F., Mecate-Zambrano, A., Rehländer, S., Hinse, S., Ludwig, S., & Brunotte, L. (2021) · Vaccines · doi:10.3390/vaccines9101052 · Cited by 27
A functional assay for serum detection of antibodies against SARS‐CoV‐2 nucleoprotein
Albecka, A., Clift, D., Vaysburd, M., Rhinesmith, T., Caddy, S., Favara, D. M., Baxendale, H., & James, L. C. (2021) · The EMBO Journal · doi:10.15252/embj.2021108588 · Cited by 26
Research progress on vaccine efficacy against SARS-CoV-2 variants of concern
Bian, L., Liu, J., Gao, F., Gao, Q., He, Q., Mao, Q., Wu, X., Xu, M., & Liang, Z. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2057161 · Cited by 31
“This mutation decreases the neutralization potency of 14 of 34 RBD-specific monoclonal antibodies.(36) Computational and Cryo-EM structural analyses of the Omicron spike proteins have revealed that Q493K, G496S, Q498 R, and N501Y mutations increase the ACE2 binding affinity by forming new salt bridges and hydrogen bon…”
BackgroundOuyang, W. O., Tan, T. J. C., Lei, R., Song, G., Kieffer, C., Andrabi, R., Matreyek, K. A., & Wu, N. C. (2022) · Science Advances · doi:10.1126/sciadv.add7221 · Cited by 28
Greaney, A. J., Eguia, R. T., Starr, T. N., Khan, K., Franko, N., Logue, J. K., Lord, S. M., Speake, C., Chu, H. Y., Sigal, A., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010592 · Cited by 29
The mechanisms of immune response and evasion by the main SARS-CoV-2 variants
Chen, Q., Zhang, J., Wang, P., & Zhang, Z. (2022) · iScience · doi:10.1016/j.isci.2022.105044 · Cited by 30
Naidoo, P., Ghazi, T., Chuturgoon, A. A., Naidoo, R. N., Ramsuran, V., Mpaka-Mbatha, M. N., Bhengu, K. N., Nembe-Mafa, N., Duma, Z., Pillay, R., et al. (2021) · Environment International · doi:10.1016/j.envint.2021.106695 · Cited by 26
Kramer, K. J., Johnson, N. V., Shiakolas, A. R., Suryadevara, N., Periasamy, S., Raju, N., Williams, J. K., Wrapp, D., Zost, S. J., Walker, L. M., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109784 · Cited by 26
Antibody-mediated immunity to SARS-CoV-2 spike
Errico, J. M., Adams, L. J., & Fremont, D. H. (2022) · Advances in immunology · doi:10.1016/bs.ai.2022.07.001 · Cited by 25
“A mildly neutralizing antibody targeting the RBD proximal side (site iv) also has been identified, namely C1791 (IC50 of 824ng/mL), which sits between the N61 and N234 linked glycans, similar to non-neutralizing mAb S2L20 (McCallum et al., 2021; Wang, Muecksch, et al., 2022) (Fig.”
Influentialde Sousa, I. P., Wallace, Z. S., Cavalcante, S. C., Ribeiro, M. P. F., Silva, J. A. B. M., Cavalcante, R. C. M., Scheuermann, R. H., & Palatnik, M. (2022) · Scientific Reports · doi:10.1038/s41598-022-21207-2 · Cited by 29
Rapid identification of neutralizing antibodies against SARS-CoV-2 variants by mRNA display
Tanaka, S., Olson, C. A., Barnes, C. O., Higashide, W., Gonzalez, M. R., Taft, J. D., Richardson, A., Martín-Fernández, M., Bogunovic, D., Gnanapragasam, P. N. P., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110348 · Cited by 20
“Of note, N-612-017 CDRH2 loop residues contact RBD positions frequently mutated among circulating variants (Deng et al., 2021; Kuzmina et al., 2021; McCallum et al., 2021a; Wang et al., 2021).”
InfluentialComputational Protein Design for COVID-19 Research and Emerging Therapeutics
Kalita, P., Tripathi, T., & Padhi, A. K. (2023) · ACS Central Science · doi:10.1021/acscentsci.2c01513 · Cited by 27
Addetia, A., Park, Y., Starr, T. N., Greaney, A. J., Sprouse, K. R., Bowen, J. E., Tilles, S. W., Voorhis, W. C. V., Bloom, J. D., Corti, D., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112621 · Cited by 24
“Pseudotyped VSV production E406W and wildtype pseudotyped VSV particles were produced as previously described.(27,28) Briefly, 5 x 10(6) HEK-293T cells were seeded in 10 cm(2) poly-D-lysine coated plates and grown overnight until they reached 70% confluency.”
Self-citationCohen, J. A., Stuart, R. M., Rosenfeld, K., Lyons, H. M., White, M. T., Kerr, C. C., Klein, D. J., & Famulare, M. (2021) · medRxiv · doi:10.1101/2021.05.31.21258018 · Cited by 22
COVID-19 pandemic: the delta variant, T-cell responses, and the efficacy of developing vaccines
Biswas, B. K., Chattopadhyay, S., Hazra, S., Hansda, A. K., & Goswami, R. (2022) · Inflammation Research · doi:10.1007/s00011-022-01555-5 · Cited by 27
Lee, D. B., Kim, H., Jeong, J. H., Jang, U. S., Jang, Y., Roh, S., Jeon, H., Kim, E. J., Han, S. Y., Maeng, J. Y., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2208425120 · Cited by 26
“Multiple variants of SARS-CoV-2, including Delta (B.1.617.2) and Omicron (B.1.1.529), have been identified globally during the pandemic (20–21 , 22).”
BackgroundInfluentialA broadly generalizable stabilization strategy for sarbecovirus fusion machinery vaccines
Lee, J., Stewart, C., Schäfer, A., Leaf, E. M., Park, Y.-J., Asarnow, D., Powers, J. M., Treichel, C., Sprouse, K. R., Corti, D., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49656-5 · Cited by 23
“Conversely, the S N-terminal domain (NTD) is mostly targeted by variant-speci fi c neutralizing antibodies 6,19,20 .”
Self-citationAkhmetzhanov, A. R., Jung, S.-M., Cheng, H., & Thompson, R. N. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.06.028 · Cited by 22
SARS-CoV-2 Variants and Vaccination
Liu, Y., Liu, J., & Shi, P. (2022) · Zoonoses · doi:10.15212/zoonoses-2022-0001 · Cited by 23
SARS-CoV-2 Point Mutation and Deletion Spectra and Their Association with Different Disease Outcomes
Martínez‐González, B., Soria, M. E., Vázquez-Sirvent, L., Ferrer‐Orta, C., Lobo-Vega, R., Mínguez, P., de la Fuente, L., Lloréns, C., Soriano, B., Ramos, R., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00221-22 · Cited by 25
“Likewise, the generation of viral escape mutants is a 81 major concern as a potential limitation of immune and antiviral agent efficacy for 82 SARS-CoV-2 (6-10), as it has been established for other RNA viruses.”
Optimization and evaluation of a live virus SARS-CoV-2 neutralization assay
Frische, A., Brooks, P. T., Gybel‐Brask, M., Sækmose, S. G., Jensen, B. A., Mikkelsen, S., Bruun, M. T., Boding, L., Polacek, C., Jørgensen, C. S., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0272298 · Cited by 22
A perspective on SARS-CoV-2 virus-like particles vaccines
Xiaoyang, G., Xia, Y., Liu, X., Xu, Y., Lu, P., dong, Z., Liu, J., & Liang, G. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109650 · Cited by 24
Addetia, A., Stewart, C., Seo, A. J., Sprouse, K. R., Asiri, A. Y., Al-Mozaini, M., Memish, Z. A., Alshukairi, A. N., & Veesler, D. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114530 · Cited by 22
Self-citationDynamic Interactions of Fully Glycosylated SARS-CoV-2 Spike Protein with Various Antibodies
Cao, Y., Choi, Y. K., Frank, M., Woo, H., Park, S., Yeom, M. S., Seok, C., & Im, W. (2021) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.1c00552 · Cited by 24
Goes, L. R., Siqueira, J. D., Garrido, M. M., Alves, B. M., Pereira, A. C. P. M., Cicala, C., Arthos, J. A., Viola, J. P. B., & Soares, M. A. (2021) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2021.104998 · Cited by 22
Application of omics technology to combat the COVID‐19 pandemic
Yang, J., Yan, Y., & Zhong, W. (2021) · MedComm · doi:10.1002/mco2.90 · Cited by 21
From Alpha to Zeta: Identifying Variants and Subtypes of SARS-CoV-2 Via Clustering
Melnyk, A., Mohebbi, F., Knyazev, S., Sahoo, B., Hosseini, R., Skums, P., Zelikovsky, A., & Patterson, M. (2021) · Journal of Computational Biology · doi:10.1089/cmb.2021.0302 · Cited by 20
“The Epsilon variants are spreading in the United States and in 29 other countries (McCallum et al., 2021).”
Jeong, B.-S., Cha, J. S., Hwang, I., Kim, U., Adolf‐Bryfogle, J., Coventry, B., Cho, H., Kim, K., & Oh, B. (2022) · mAbs · doi:10.1080/19420862.2021.2021601 · Cited by 21
Organoid Models of SARS-CoV-2 Infection: What Have We Learned about COVID-19?
Tran, B. M., Deliyannis, G., Hachani, A., Earnest, L., Torresi, J., & Vincan, E. (2022) · Organoids · doi:10.3390/organoids1010002 · Cited by 22
“429) [45], which have been associated with greater transmission and disease severity and, for B.”
BackgroundMolecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy
Damavandi, A. R., Dowran, R., Sharif, S. A., Kashanchi, F., & Jafari, R. (2022) · Medical Microbiology and Immunology · doi:10.1007/s00430-022-00729-6 · Cited by 23
“L452Q is similar to L452R, which is present in Epsilon, Delta, and Iota variants and also associated with resistance to neutralizing antibodies [98, 99].”
BackgroundDesign of customized coronavirus receptors
Liu, P., Huang, M., Guo, H., McCallum, M., Si, J.-Y., Chen, Y., Wang, C., Xiao, Y., Shi, L., Xiong, Q., et al. (2024) · Nature · doi:10.1038/s41586-024-08121-5 · Cited by 23
“Relative to closed S2L20-bound spike structures 51,52 , the open S2L20-bound spike structure exhibits a repositioning of the NTDs and bound S2L20 along with stabilization of a conformation of the N234 glycan that would be sterically incompatible with subsequent RBD closing (Fig.”
Self-citationSARS-CoV-2 spike conformation determines plasma neutralizing activityPreprint
Bowen, J. E., Walls, A. C., Joshi, A., Sprouse, K. R., Stewart, C., Tortorici, M. A., Franko, N., Logue, J. K., Mazzitelli, I. G., Tilles, S. W., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.19.473391 · Cited by 21
“…of the SARS-CoV-2 NTD among variants and sarbecoviruses, which is associated with a narrow specificity of NTD neutralizing antibodies ( 20 , 23 , 54 , 61 – 63 ), and (ii) the description of multiple broadly neutralizing antibodies recognizing distinct RBD antigenic sites ( 12 – 14 , 16 , 18 ,…”
Self-citationThe Evolving Faces of the SARS-CoV-2 Genome
Schmidt, M., Arshad, M., Bernhart, S. H., Hakobyan, S., Arakelyan, A., Loeffler‐Wirth, H., & Binder, H. (2021) · Viruses · doi:10.3390/v13091764 · Cited by 22
Structural effects of spike protein D614G mutation in SARS-CoV-2
Dokainish, H., & Sugita, Y. (2022) · Biophysical Journal · doi:10.1016/j.bpj.2022.11.025 · Cited by 23
“, H69-, H70-, and R158G) with direct effects on NTD antibody binding (5,23); and 3) distal mutations in SD1 and SD2 with allosteric effects on the RBD structure and motion, such as the D614G and A570D mutations, which shift RBD down/ up populations (12,24,25).”
Burke, B. E., Rocha, S. M., Zhan, S., Eckley, M., Reasoner, C., Addetia, A., Lewis, J., Fagre, A. C., Charley, P. A., Richt, J. A., et al. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011728 · Cited by 21
Self-citationStreblow, D. N., Hirsch, A. J., Stanton, J. J., Lewis, A. D., Colgin, L. M. A., Hessell, A. J., Kreklywich, C. N., Smith, J. L., Sutton, W. F., Chauvin, D., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42440-x · Cited by 20
Manak, M., Gagnon, L., Phay-Tran, S., Levesque-Damphousse, P., Fabié, A., Daugan, M., Khan, S., Proud, P. C., Hussey, B., Knott, D., et al. (2024) · The Lancet Microbe · doi:10.1016/s2666-5247(23)00324-5 · Cited by 18
Possible Targets of Pan-Coronavirus Antiviral Strategies for Emerging or Re-Emerging Coronaviruses
Li, X., Zhang, L., Chen, S., Ouyang, H., & Ren, L. (2021) · Microorganisms · doi:10.3390/microorganisms9071479 · Cited by 21
SARS-CoV-2: The Interplay Between Evolution and Host Immunity
Case, J. B., Jain, S., Suthar, M. S., & Diamond, M. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-083122-043054 · Cited by 29
“…was the emergence of variants encoding K417T/N and E484K (Beta and Gamma), N501Y (Alpha, Beta, and Gamma), or L452R (Delta) mutations, which escaped therapeutic mAbs and impaired the neutralizing activity of polyclonal sera derived from vaccinated or infected individuals (Figure 2b) (184–190).”
Designed miniproteins potently inhibit and protect against MERS-CoV
Ragotte, R. J., Tortorici, M. A., Catanzaro, N., Addetia, A., Coventry, B., Froggatt, H. M., Lee, J., Stewart, C., Brown, J. T., Goreshnik, I., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115760 · Cited by 23
“The broadly neutralizing activity of nTrimer1 against a panel of MERS-CoV S variants demonstrates some degree of resilience to viral evolution and antigenic changes, as observed for SARS-CoV-2 variants throughout the COVID-19 pandemic 41,44–48 .”
Self-citationBlain, H., Tuaillon, É., Gamon, L., Pisoni, A., Miot, S., Delpui, V., Si-Mohamed, N., Niel, C., Rolland, Y., Montès, B., et al. (2021) · Allergy · doi:10.1111/all.15142 · Cited by 18
Point-of-Care Diagnostic Tools for Surveillance of SARS-CoV-2 Infections
Sakthivel, D., Delgado-Diaz, D. J., McArthur, L., Hopper, W., Richards, J. S., & Narh, C. A. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.766871 · Cited by 19
“429), which have been associated with high transmissibility and disease severity in many geographical regions (58, 59).”
Background
Metadata
- Authors
- McCallum, M., Bassi, J., De Marco, A., Chen, A., Walls, A. C., Di Iulio, J., Tortorici, M. A., Navarro, M.-J., Silacci-Fregni, C., Saliba, C., Sprouse, K. R., Agostini, M., Pinto, D., Culap, K., Bianchi, S., Jaconi, S., Cameroni, E., Bowen, J. E., Tilles, S. W., Pizzuto, M. S., Guastalla, S. B., Bona, G., Pellanda, A. F., Garzoni, C., Van Voorhis, W. C., Rosen, L. E., Snell, G., Telenti, A., Virgin, H. W., Piccoli, L., Corti, D., & Veesler, D.
- Affiliations
- University of Washington (US)
- Vir Biotechnology (Switzerland) (CH)
- Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
- VIR Biotechnology (United States) (US)
- Vir Biotechnology, San Francisco, CA 94158, USA.
- Independent physician, 6828 Balerna, Switzerland.
- Clinica Luganese Moncucco (CH)
- Clinical Research Unit, Clinica Luganese Moncucco, 6900 Lugano, Switzerland.
- Center for Emerging and Re-emerging Infectious Diseases, Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA.
- Corresponding author
- McCallum, Matthew
- Bassi, Jessica
- Chen, Alex
- Walls, Alexandra C.
- Piccoli, Luca
- Corti, Davide
- Veesler, David
- ORCID
- McCallum, Matthew
- Bassi, Jessica
- De Marco, Anna
- Chen, Alex
- Walls, Alexandra C.
- Di Iulio, Julia
- Tortorici, M. Alejandra
- Navarro, Mary-Jane
- Saliba, Christian
- Sprouse, Kaitlin R.
- Pinto, Dora
- Culap, Katja
- Bianchi, Siro
- Jaconi, Stefano
- Cameroni, Elisabetta
- Bowen, John E.
- Tilles, Sasha W.
- Pizzuto, Matteo Samuele
- Guastalla, Sonja Bernasconi
- Bona, Giovanni
- Pellanda, Alessandra Franzetti
- Garzoni, Christian
- Van Voorhis, Wesley C.
- Rosen, Laura E.
- Snell, Gyorgy
- Telenti, Amalio
- Virgin, Herbert W.
- Piccoli, Luca
- Corti, Davide
- Veesler, David
- Venue
- Science
- Published
- 2021-08-06
- Volume
- 373
- Issue
- 6555
- Pages
- 648-654
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC9835956
- OpenAlex
- W3174747632
- Cited by
- 412
- References
- 90
- Citations by year
- 2026: 12 · 2025: 13 · 2024: 25 · 2023: 56 · 2022: 165 · 2021: 141
- FWCI
- 31.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (DP1AI158186, HHSN272201700059C, U01 AI151698-01)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Keywords
- SARS-CoV-2, immune evasion, spike protein mutations, L452R, N-terminal domain, receptor binding domain, neutralizing antibodies, monoclonal antibodies, signal peptide cleavage site, disulfide bonds, mRNA vaccines, convalescent plasma, neutralization titers
- MeSH terms
- Protein Domains, COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, 2019-nCoV Vaccine mRNA-1273, Antibodies, Monoclonal, Antibodies, Viral, Antigens, Viral, Humans, Models, Molecular, Mutation, Neutralization Tests, Protein Conformation, Amino Acid Substitution, Cryoelectron Microscopy, Protein Subunits, Protein Interaction Domains and Motifs, Immune Evasion, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.